{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:35:16Z","timestamp":1767162916324,"version":"build-2238731810"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":6434,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1111\/j.1600-6143.2005.01063.x","type":"journal-article","created":{"date-parts":[[2005,9,11]],"date-time":"2005-09-11T09:44:24Z","timestamp":1126431864000},"page":"2521-2530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["Three\u2010Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients"],"prefix":"10.1016","volume":"5","author":[{"given":"\u0160tefan","family":"V\u00edtko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimund","family":"Margreiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem","family":"Weimar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Dantal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"\u00d8yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik G.","family":"Viljoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Filiptsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Cretin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1600-6143.2005.01063.x_bib1","first-page":"384","article-title":"Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies","volume":"7","author":"Olyaei","year":"2001","journal-title":"Curr Opin Crit Care"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199512000-00019","article-title":"Rapamune (Sirolimus, rapamycin): An overview and mechanism of action","volume":"17","author":"Sehgal","year":"1995","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative. Pharmacologic properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00007890-199707150-00007","article-title":"SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine","volume":"64","author":"Schuurman","year":"1997","journal-title":"Transplant"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac\u2010transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib6","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1034\/j.1600-6143.2002.20301.x","article-title":"Call for revolution: A new approach to describing allograft deterioration","volume":"2","author":"Gourishankar","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib8","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1016\/S0041-1345(01)02369-7","article-title":"The role of Certican\u2122 (everolimus, RAD) in the many pathways of chronic rejection","volume":"33","author":"Nashan","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib9","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1517\/14656566.4.12.2325","article-title":"Mycophenolate mofetil in solid\u2010organ transplantation","volume":"4","author":"Srinivas","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007890-199701150-00008","article-title":"Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double\u2010blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups","volume":"63","author":"Halloran","year":"1997","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00007890-199908150-00011","article-title":"Mycophenolate mofetil in renal transplantation: 3\u2010year results from the placebo\u2010controlled trial","volume":"68","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib12","doi-asserted-by":"crossref","unstructured":"Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405\u20139.","DOI":"10.1097\/00007890-200006150-00033"},{"issue":"Suppl 9","key":"10.1111\/j.1600-6143.2005.01063.x_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-6135.2004.00397.x","article-title":"Immunosuppression: Practice and trends","volume":"4","author":"Kaufman","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib14","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican\u2122) 12\u2010month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"V\u00edtko","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib15","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib16","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/00007890-199806150-00007","article-title":"A blinded long\u2010term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation","volume":"65","author":"Mathew","year":"1998","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/01.ASN.0000113248.59077.76","article-title":"Long\u2010term benefits with sirolimus\u2010based therapy after early cyclosporine withdrawal","volume":"15","author":"Kreis","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3\u2010year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced\u2010exposure cyclosporine in de novo renal\u2010transplant recipients: A three\u2010year phase II, randomized, multicenter, open\u2010label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post\u2010transplant year: Pharmacokinetics, exposure\u2010response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","article-title":"Exposure\u2010response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range","volume":"73","author":"Kovarik","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1034\/j.1600-6143.2003.00107.x","article-title":"Pharmacokinetics of an everolimus\u2010cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation","volume":"3","author":"Kovarik","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjcard.2004.08.074","article-title":"Angiographic results of the first human experience with everolimus\u2010eluting stents for the treatment of coronary lesions (the FUTURE I trial)","volume":"95","author":"Costa","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6\u2010month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/dot.2004.40.2.799422","article-title":"Everolimus: A proliferation signal inhibitor targeting primary causes of allograft dysfunction","volume":"40","author":"Kovarik","year":"2004","journal-title":"Drugs Today"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib26","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00007890-199912270-00011","article-title":"Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients","volume":"68","author":"Humar","year":"1999","journal-title":"Transplantation"},{"issue":"Suppl 8","key":"10.1111\/j.1600-6143.2005.01063.x_bib27","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ajhp\/60.suppl_8.S5","article-title":"Costs and consequences of cytomegalovirus disease","volume":"60","author":"Schnitzler","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007691-200202000-00007","article-title":"Factors associated with long\u2010term renal allograft survival","volume":"24","author":"Kaplan","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib29","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/j.1600-6143.2004.00624.x","article-title":"Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival","volume":"4","author":"Meier\u2010Kriesche","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00002018-200528020-00006","article-title":"Benefit\u2010risk assessment of sirolimus in renal transplantation","volume":"28","author":"Kuypers","year":"2005","journal-title":"Drug Saf"},{"key":"10.1111\/j.1600-6143.2005.01063.x_bib31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/14656566.6.3.479","article-title":"Sirolimus: A new option in transplantation","volume":"6","author":"Mota","year":"2005","journal-title":"Expert Opin Pharmacother"}],"updated-by":[{"DOI":"10.1111\/j.1600-6143.2005.01206.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000}}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-6143.2005.01063.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522294258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522294258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-6143.2005.01063.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:35:07Z","timestamp":1761626107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522294258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S1600613522294258"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01063.x","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three\u2010Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01063.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}